Epitalon
| Category | Bioregulators |
| Goals | Longevity & Anti-Aging |
| Evidence level | Preclinical (rodent + cell-culture; mostly one Russian research lineage) |
| Legal status | Research-only — not approved for human use |
| FDA status | Not FDA-approved; on PCAC 503A agenda Jul 24, 2026 (use evaluated: insomnia) |
| Half-life | Very short (minutes); human PK not well characterized |
| Routes | Subcutaneous · Intramuscular · Intranasal |
| CAS / MW / Sequence | 307297-39-8 · 390.35 g/mol · AEDG (Ala-Glu-Asp-Gly, 4 aa) |
| Last reviewed | 2026-06-07 |
In one line
A synthetic AEDG tetrapeptide (a “Khavinson bioregulator”) derived from a pineal extract, studied mainly in animals and cell cultures for telomerase activation and longevity-related effects.
Evidence at a glance
Nearly all Epitalon data originates from a single Russian research group (Khavinson and colleagues), and no placebo-controlled human trial has been published. Telomere/longevity claims far outrun the available human evidence. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a peptide extract of the pineal gland.
- Best known for claims of telomerase activation and telomere lengthening — demonstrated in cell cultures and some rodent studies, not in controlled human trials.
- Proposed to act epigenetically (binding DNA / histone H1) rather than via a classical surface receptor.
- Not FDA-approved; removed from compounding-pharmacy eligibility in 2023. Sold as a research chemical.
- A Khavinson-class bioregulator, often discussed alongside Thymalin in longevity protocols.
What Is It
Epitalon (also spelled Epithalon; the original natural extract is called Epithalamin) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues, modeled on a peptide fraction isolated from the pineal gland. It belongs to the “peptide bioregulator” class — very short peptides hypothesized to regulate tissue-specific gene expression. It does not occur naturally as this defined synthetic peptide.
Mechanism of Action
Mechanisms are largely proposed from cell-culture and animal work, much of it from one research lineage:
- Telomerase activation (cell culture) — reported to upregulate the catalytic telomerase subunit and lengthen telomeres in human fibroblast cultures.
- Epigenetic / gene-expression effects (in vitro) — proposed to bind DNA (including methylated cytosine) and linker histone H1, influencing transcription, rather than acting through a classical membrane receptor.
- Pineal / circadian modulation (animal) — proposed to normalize melatonin rhythms and pineal function in aged animals.
- Antioxidant / lifespan effects (animal) — reported increases in median lifespan in rodent and invertebrate models.
Limitations
The headline telomerase finding rests on a small number of in-vitro studies. Independent replication outside the original group is limited, and the molecular target is not firmly established.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Telomerase activation / telomere lengthening | Preclinical | Human cell cultures; not shown in controlled human trials |
| Lifespan extension | Preclinical | Rodent/invertebrate models, largely one lab |
| Melatonin / circadian normalization | Preclinical | Aged-animal data |
| Antioxidant / age-related disease markers | Preclinical | Animal and small uncontrolled human reports |
| General “anti-aging” in humans | Anecdotal | Popular claims; no placebo-controlled human data |
Reported Dosing
Not medical advice
Protocols as reported in community sources and non-clinical literature. There is no established human therapeutic dose. See Reconstitution & Dosing Math and Injection Technique.
| Route | Dose (reported) | Frequency | Cycle |
|---|---|---|---|
| Subcutaneous | ~5–10 mg/day | Daily | ~10–20 day course, 1–2×/year |
| Intramuscular | ~5–10 mg/day | Daily | ~10–20 day course |
| Intranasal | Reported, variable | Daily | Variable |
Pharmacokinetics
Like most small peptides, Epitalon is expected to have a very short circulating half-life (minutes), being rapidly hydrolyzed by peptidases. This is the rationale behind the reported short daily “courses.” Detailed human pharmacokinetic data are not well characterized. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Human safety data are sparse; “well tolerated” claims rest largely on small, uncontrolled, mostly non–English-language reports — absence of reported harm is not proof of safety.
- Anecdotal: injection-site reactions, transient headache, drowsiness — not systematically documented.
- Theoretical concern: any agent claimed to activate telomerase raises speculative questions about cancer-cell proliferation; not adequately studied in humans.
- Sourcing risk: as a research chemical, identity and purity vary — see Sourcing and Red Flags & Scams.
- See Side Effects & Risk Management.
Cycling
Anecdotal protocols run short 10–20 day courses once or twice per year rather than continuous dosing. No evidence-based cycling standard exists. See Cycling.
Stacks It Appears In
- Longevity-oriented bioregulator combinations with Thymalin (immune) — described in Khavinson-group reports.
- Frequently discussed alongside NAD+ and other longevity agents in community protocols.
Comparisons
- vs Thymalin — both are Khavinson bioregulators; Epitalon targets pineal/telomere themes, Thymalin targets thymic/immune function.
Sourcing & Quality
Sold almost exclusively as a lyophilized “research chemical,” so identity and purity are not guaranteed. Evaluate before trusting any product: How to Read a CoA, Sourcing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-07.) Not FDA-approved for any use. The FDA previously flagged Epitalon among peptide bulk substances raising compounding-safety concerns (interim 503A review, 2023). Epitalon-related bulk drug substances (Epitalon free base / acetate) are now on the agenda of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 24, 2026, being considered for inclusion on the 503A Bulks List; the use FDA evaluated is insomnia (public docket FDA-2025-N-6895). Inclusion would only determine eligibility for traditional (503A) pharmacy compounding — it is not drug approval. Most published human data are Russian-language and predate modern trial standards. Status varies by country. See Regulatory & Legal Status.
FAQ
Is Epitalon FDA-approved? No. It is not approved for human use and was removed from compounding eligibility in 2023.
Does Epitalon lengthen telomeres in people? Telomere/telomerase effects are reported in cell cultures and some animal work. There is no placebo-controlled human trial demonstrating this clinically.
Is it the same as Epithalamin? Epithalamin is the original pineal extract; Epitalon/Epithalon is the synthetic AEDG tetrapeptide derived from studying it.
What is it usually combined with? In Khavinson-group longevity work it is often paired with the thymic bioregulator Thymalin.
References
- Khavinson V.K. et al. — multiple reviews on peptide bioregulators and AEDG (e.g. Bulletin of Experimental Biology and Medicine; Biogerontology).
- “Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties.” PMC (2025). PMC11943447
- “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology (2025).
- U.S. FDA (2023). Peptide bulk substances flagged under the interim section 503A review (includes Epitalon).
- U.S. FDA (2026). “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” — Epitalon (free base/acetate), use evaluated: insomnia; Docket FDA-2025-N-6895. fda.gov
← Bioregulators · Home Educational information only — not medical advice. See Disclaimer.